Legend Capital Archives

Legend Capital Portfolio Company Yonz Technology Lists on the Main Board of the Shanghai Stock Exchange Successfully

On June 26, Legend Capital‘s portfolio company, Yonz Technology Co., Ltd. (603381.SH), was successfully listed on the Main Board of the Shanghai Stock Exchange.

Founded in 2016, Yonz Technology is mainly engaged in the R&D, production, sales and application of green energy structural materials. With years of development, the company has become a leading manufacturer of aluminum alloy photovoltaic structural parts in China, with products coverage of photovoltaic frames, Building Integrated Photovoltaics (BIPV), and photovoltaic bracket structural parts. Being lightweight, high stability, weather- and corrosion-resistance, the company’s photovoltaic frame products are mainly used to protect the edges, strengthen the sealing performance and improve the overall mechanical strength of photovoltaic modules, so as to facilitate better transportation and installation.

Since its establishment, the company has always placed great attention on improving its innovation and R&D capabilities. Its core technological system, involving a complete production chain including product structure design, casting process technology, mold design and production, profile extrusion technology, surface treatment technology and deep processing technology, has been applied in large-scale production. As of December 31, 2023, Yonz Technology and its subsidiaries owned 81 registered trademarks, 135 authorized patents, and 2 software copyrights. According to the data from China Photovoltaic Industry Association in 2023, from 2020 to 2022, the company’s market share of the solar frame products was ranked first among global rivalries, stating a leading position of Yonz Technology in manufacturing technology and product quality within the industry.

Wang Xianli, Chairman of Yonz Technology, said: After the listing, Yonz Technology will adhere to the mission of ‘making the best integration of green energy and the world’. While further improving our present business of solar module frames, we will continuously cooperate with upstream and downstream partners in the green energy domain at the same time, further extending the PV industry chain. We will also improve our products’ added values and persistently contribute to the domestic clean energy and PV industry development.

Legend Capital invested in Yonz Technology in 2021 and provided proactive value-adding services in various aspects including lean production, talent introduction, strategic planning, global investment, and corporate management, enabling Yonz Technology to improve its R&D capabilities and achieve significant growth in revenue and profit.

Legend Capital said: Congratulations to Yonz Technology. Its Chairman Mr. Wang is an outstanding entrepreneur with extensive experiences and strong industrial networks, which helps to bring together a strong management team. Yonz Technology has always focused on improving its own innovation and R&D since its establishment and will further consolidate its industry position by leveraging the advantages to become a world-class, greener structural material manufacturer.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, Seoul and Singapore.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Legend Capital’s Portfolio Company Aidite Lists on the ChiNext Successfully

On June 26, Legend Capital’s portfolio company, Aidite (301580.SZ), was successfully listed on the ChiNext of the Shenzhen Stock Exchange.

Founded in 2007, Aidite is an industry-leading provider of oral prosthodontics materials and dental digital equipment, covering business for more than 120 countries and regions around the world. The company has always been committed to R&D, production and sales of internationally competitive oral prosthodontics materials including zirconia porcelain blocks. Aidite designs and sells dental digital equipment on the basis of its in-depth understanding of the oral medical industry and good customer base, and through technological innovation and digitalization, the company transforms traditional dentistry and promotes digitization and intelligence of the dental industry.

Since its establishment, Aidite has adhered to the concept of innovation-driven development, focusing on renovating dental technology to launch products that meet market demand and improve product competitiveness to expand international market share. Through long-term R&D of zirconium oxide preparation technology, the company has formed a full product series covering the high, middle and low-end market segments. Relying on its long-term and profound accumulation in zirconia materials and its understanding of the digital production process of dentures, the company vigorously expands its dental digital equipment business and promotes digitization and intelligence of the dental restoration field. As of December 31, 2023, Aidite and its subsidiaries have acquired a total of 93 patents, including 92 valid domestic patents and 1 overseas invention patent.

LI Hongwen, Chairman of Aidite, said: Aidite will lead and focus more on innovations after the listing. The company will continue to build technical barriers and cost advantages for core products, and through leveraging the comprehensive advantages of cloud platform digital services and digital equipment with a higher degree of automation, Aidite is also committed to promoting technological transformation of dental medical digital production and contributing to improving the quality and efficiency of the industry. At the same time, Aidite will continue to cooperate with head dental colleges and research institutions actively to promote the industrial application of cutting-edge dental diagnosis and treatment technologies, as well as enhance international market expansion with a vision to become a global-leading digital dental solution provider.

Legend Capital invested in Aidite at the end of 2019 and is the company’s earliest and largest external institutional investor. After the investment, Legend Capital has continued to support the company’s development, including providing assistance in the company’s equity governance, executive talent introduction, follow-up financing, strategic positioning, and domestic and foreign M&A.

Legend Capital said: There is huge room for growth in the industrial chain of the oral medical industry. As a leading company in oral prosthodontics materials, Aidite has a clear strategy, extending upstream and downstream around the oral materials industry, and seizing the digital opportunities in the dental industry to continuously improve its overall R&D capabilities. We hope that the company will take the listing as an opportunity to further enhance its brand influence both domestically and internationally, attracting more customers at home and abroad and taking a leading role in accelerating the overseas expansion of Chinese dental brands. We believe that under the leadership of Chairman Mr. LI Hongwen, the company will bring more products to benefit more people and create greater value for customers, the industry and society through continuous R&D and innovation. Congratulations to Aidite for its successful listing!

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Legend Capital Portfolio Company Qunabox Group Lists on the Main Board of the HKEX Successfully

On May 27, Legend Capital’s portfolio company, Qunabox Group (HKG: 0917), was successfully listed on the main board of the Hong Kong Stock Exchange with an opening price of HKD33 per share, a 32% increase from the issue price of HKD25 per share.

Founded in 2013, Qunabox Group is an AIoT marketing service provider focusing on fast-moving consumer goods (“FMCG”). Through utilizing its broad network of vending machines with interactive marketing functions, Qunabox Group provides target consumers with convenient and interesting experience in testing and accessing FMCG that it served, while successfully soliciting and completing necessary interaction and feedback.

As of December 31, 2023, Qunabox Group operated 7,543 vending machines in 22 cities in China including all the tier one cities and many new tier one cities. Substantially all of Qunabox Group’s vending machines are located in commercial properties with an aim to cover the major consumer groups of FMCGs, and by attracting consumers for interaction and converting them into users of their online platform “Quna” with a combination of online and offline channels, Qunabox Group had approximately 15.9 million AAUs in 2023. According to CIC, it provided marketing service to 472 brand customers for approximately 1,400 SKUs of FMCG products, including products from 74 emerging brands among the top 100 emerging brands in the industries of beverages, food and daily necessities in China.

Legend Capital invested in Qunabox Group in 2016 and has accompanied the company in its development from a vending machine-style outdoor marketer to a comprehensive marketing service provider integrating AI technology, IoT technology, and interactive sensing technology. After the investment, Legend Capital actively helped the company improve its strategic management and organizational management capabilities, and provided the company with value-added services in multiple dimensions such as business connection, finance, legal compliance and talent recruitment.

Legend Capital said: “Qunabox Group represents an upgrade of consumer services driven by technological innovation. By utilizing various AIoT technologies, it has transformed traditional low-efficiency free trial marketing services into a new generation of service model that is interesting for consumers, data-driven for brands, and significantly improves efficiency for the industry. With the advancement of large-scale AI models, Qunabox Group will become the best platform for AI applications in digital marketing. At the same time, Qunabox Group will continuously expand into overseas markets and enhance its global presence. The team has achieved remarkable achievements under the leadership of the company’s chairwoman, Ms. Yin Juehui, one of the rare Chinese entrepreneurs who possess both global vision and strong execution capabilities. Congratulations to Qunabox Group on its successful listing in Hong Kong.”

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Legend Capital Portfolio Company ZKH Lists on the New York Stock Exchange Successfully

On the evening of December 15th, Beijing time, Legend Capital‘s portfolio company, ZKH Group Limited (ZKH) (NYSE: ZKH), was officially listed on the New York Stock Exchange.

ZKH is a leading maintenance, repair and operations (MRO) procurement service platform in China. The company provides one-stop MRO procurement and management services for its customers and offers digital and fulfillment solutions for participants along the industry value chain.

ZKH offers a broad range of MRO products covering all major MRO product lines and over 17 million SKUs. The company’s product lines can be broadly divided into five categories: spare parts, chemicals, manufacturing parts, general consumables, and office supplies, which consist of 32 product lines available on its platform. It has established long-term cooperation with more than 60,000 advanced manufacturing customers. At present, ZKH has 30 distribution centers and 96 transit warehouses, continuing the dedication to building a nationwide fulfillment network to deliver last-mile delivery services for customers.

Legend Capital co-led ZKH’s Series C financing in 2018 and made additional investments in the company’s subsequent financing rounds in 2019 and 2020. After the investment, Legend Capital has kept giving support and assistance to the company in multiple aspects, including business resource introduction, corporate strategy, follow-up financing and listing-related work.

Legend Capital stated: “After years of development, ZKH has demonstrated competitive strengths in the industry based on its differentiated capabilities, including one-stop supply chain capabilities covering all major product categories and procurement channels, delivery capabilities characterized by distributed warehousing and instant delivery, and service capabilities featuring online/offline products and advantageous product lines. At the same time, the company has an efficient and highly capable team consisting of outstanding talents in multiple fields, including industrial products, e-commerce, and logistics, and the management team, led by the founder of the company, Mr. CHEN Long, has also demonstrated strong resource integration capabilities. The approval for listing has reflected the resilience of ZKH’s business development. Congratulations!”

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Co-led by Legend Capital, Leadrive Completes Series D Financing Round

On October 9th, Leadrive Technology (Leadrive) announced the completion of its Series D financing round, with an amount of over RMB600 million. Legend Capital, as an existing shareholder of Leadrive, co-led the financing round to continuously give the company its support.

The Series D financing round was completed in succession to Volvo Car Technology Fund AB’s strategic investment in Leadrive for its Series C+ round over the past month. Leadrive has been supported and favored by various investors, including industrial capital, private equity investment, and insurance funds.

The funds raised in this round will be mainly used to supplement operating cash flow, expand production capacity, and develop next-generation power modules, power bricks, and silicon carbide (SiC) technology.

Legend Capital stated: “Currently, the global trend of vehicle electrification is accelerating, leading to a systemic transformation of the global automotive supply chain system and creating favorable opportunities for technology innovators. Leadrive is featured with rare forward-looking R&D capabilities in automotive power semiconductors and motor controllers in China. Additionally, with the long-term accumulation in SiC third-generation power semiconductors, Leadrive’s forward-looking layout will translate into large-scale deliveries within the next 2 to 4 years. We are honored to participate in Leadrive’s continuous innovation and pursuit of excellence and believe that with its global vision and layout, Leadrive will fully grasp the opportunities presented by the transformation of the automotive supply chain system and grow into an iconic enterprise with global competitiveness.”

Since its establishment in 2017, Leadrive has consistently focused on R&D and breakthroughs in core technologies. It has developed and launched several technology-leading power semiconductor modules and electric drive solution platforms, which have been put into mass production. As of now, Leadrive has achieved designated and mass production on over 30 flagship models of leading passenger vehicle OEMs at home and abroad. The company has also established deep cooperation with leading international OEMs and Tier 1 suppliers, ensuring the high-quality and stable supply of electric control systems and power module products in overseas markets.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Legend Capital Portfolio Company TUHU Car Lists on the Main Board of the HKEX Successfully

On September 26, Legend Capital‘s portfolio company, TUHU Car (HKG: 9690), was successfully listed on the main board of the Hong Kong Stock Exchange.

Founded in 2011, TUHU Car is a leading integrated online and offline platform for automotive service in China. By providing a digitalized and on-demand service experience underpinned by the customer-centric model and streamlined supply chain, TUHU Car directly addresses car owners’ diverse product and service needs, creating an automotive service platform consisting of car owners, suppliers, automotive service stores and other participants. TUHU Car’s platform serves most of the passenger vehicle models sold in China, fulfilling a wide spectrum of automotive service demands ranging from tires and chassis parts replacement to auto maintenance, repair, detailing, and more. By providing sporadic automotive service demands onto one platform, customer engagement is significantly increased as compared to the traditional offline automotive service model that is highly dependent on localized service demands.

According to the CIC Report, as of the first half of 2023, TUHU Car had more than 100 million registered users on their flagship “TuHu Automotive Service” app and online interfaces. The company had over 18 million transacting users in the last twelve months ended June 30 2023. With the growing service network, TUHU Car has 5,129 TUHU Workshops and over 20,000 partner stores across China, covering a majority of prefecture-level cities and making the company’s platform the largest car owner community amassed by automotive service providers in China. According to the CIC Report, China’s automotive service market reached RMB1.2 trillion in 2022 and is expected to reach RMB1.9 trillion in 2027. As a necessity for daily life and travel, automobile services have the characteristics of recession-resilient and steadily growing.

Legend Capital has long supported TUHU Car’s development as one of the company’s early investors. Legend Capital exclusively invested in TUHU Car’s Series A financing in 2014 and subsequently made additional investments in the company in its multiple rounds of financing from 2014 to 2020.

China’s automotive service market was still in an extremely early stage when Legend Capital initially invested in TUHU Car. At the beginning of the investment cooperation, TUHU Car only had 27 employees, with its office set up in a warehouse and 50 offline partner stores, and the model of “online order + offline installation” pioneered by TUHU Car had just started in Shanghai. After the investment, Legend Capital assisted the company in completing subsequent multiple rounds of financing and provided support and assistance in strategic planning, management operations, team incentives, and business resources, accompanying the company to grow into a leading integrated online and offline platform for automotive service in China.

As a valuable partner of TUHU Car, Legend Capital would like to congratulate the company sincerely: “Congratulations to TUHU Car and its team on the successful listing. Legend Capital has long been focusing on the empowerment of technology and Internet technology in traditional industries. China’s automotive service market has huge room for development, and TUHU Car has demonstrated a high growth rate in its business after years of development and accumulation. Over the nine years of investment cooperation between Legend Capital and TUHU Car, a deep friendship has been established between us. We are inspired by the company’s management team for the relentless efforts in leading TUHU Car towards success and continuously creating value, and we also greatly admire the TUHU Car team for seizing the opportunity to cut into the automotive service market from Internet applications in the early stages of industry development and achieving rapid growth of the company. The listing is believed to enhance TUHU Car’s brand and supply chain advantages further, continuously solidifying the company’s leading position in the industry.”

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital.

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Legend Capital Portfolio: Nuclei, the World’s First RISC-V CPU IP Vendor, Accomplishes ISO 26262 ASIL-D Product Certificate

Legend Capital‘s portfolio company, Nuclei System Technology, a leading RISC-V CPU IP vendor in China, announces that NA900 has been certified to be compliant to ASIL D requirements of ISO 26262 standards for both systematic fault and random hardware fault. NA900 becomes the world’s first RISC-V CPU IP achieving ISO 26262 ASIL D product certificate.
The NA900 processor has been developed as a hardware SEooC according to ISO 26262-10. The development meets the applicable ASIL D design specification, implementation and verification requirements of ISO 26262 parts 4,5,7,8,9 as guided by ISO 26262-10, and the functional safety management requirements per ISO 26262-2. According to the official assessment report, NA900 meets both systematic capability and hardware safety integrity with ASIL D. Nuclei is the first RISC-V CPU IP vendor in the world to get ASIL D product certificate.

NA900 is a configurable CPU core features a 9-stage, dual-issue pipeline supporting RISC-V RV32IMACFDPB ISA.

NA300D has been assessed according to ISO 26262-5:2018 with SGS and gets ASIL D Ready certificate for hardware safety integrity. According to SGS assessment report, NA300D meets the architectural metrics SPFM and LFM with ASIL D target values.

NA300 is a configurable CPU core features a 3-stage, single-issue pipeline supporting RISC-V RV32IMACFDPB/Zc ISA.

“It’s a great honor for Nuclei to obtain the world’s first ISO 26262 ASIL D product certificate of RISC-V CPU IP, which is a huge achievement of the team. This is a significant milestone not only for Nuclei, but also for the entire RISC-V ecosystem booming in the automotive industry. Together with our partners, Nuclei will continue expanding FUSA compliant product portfolio in the near future.” said Jianying Peng, CEO of Nuclei.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

About Nuclei System Technology
Established in 2018, Nuclei System Technology is a leading RISC-V CPU IP vendor in China. Nuclei dedicates to developing high-performance/low-power processors and their associated SoC platforms to serve the rapidly growing computing applications worldwide.

Starting from scratch, Nuclei provides a full series of processors that can meet various markets and applications, including RISC-V 32-bit (N/U classes) & 64-bit architecture(NX/UX classes), security (NS class) & automotive (NA class), etc. As of today, more than 150 customers have officially licensed Nuclei’s processor IPs. covering MCU, AIoT, 5G communication, industrial control, artificial intelligence, automotive electronics, storage, Ethernet, etc.
https://nucleisys.com

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Backed by Legend Capital, the Chinese Pet Food Industry Leader Gambol Pet Goes Public Successfully

On August 16, Legend Capital‘s portfolio company, Gambol Pet (301498.SZ), was successfully listed on the ChiNext Market of the Shenzhen Stock Exchange. Gambol Pet plans to issue 40,004,500 shares at an offering price of RMB39.99 per share, with an estimated total fundraising of approximately RMB1.6 billion.

Engaged in the R&D, production and sales of pet food and providing multi-series products mainly for dogs and cats, Gambol Pet was founded in 2006 and is a leading pet food company in China. The company started with overseas OEM/ODM businesses and has gradually become a recognized supplier for international enterprises such as Walmart and Spectrum Brands. With the rapid growth of the pet food market in China, Gambol Pet has systematically expanded its presence in the Chinese market since 2013 and established its own brand, Myfoodie, which achieved full-category coverage in pet food, including pet staple food, snacks and health care products.

As one of the leading companies in the pet food industry, Gambol Pet adheres to the concept of “Global Vision, Continuous Innovation” and is committed to producing nutritious and healthy pet food that consumers need. Through its reliable product quality, continuous innovation and efficient sales network, the company made the best of the opportunity of the rapid expansion of the pet food demand in China and has formed a core lineup of proprietary brands with Myfoodie at the center.

Legend Capital invested in Gambol Pet in 2019 and 2020 and helped the company transform from an export-oriented OEM enterprise to a leading pet food enterprise in China driven by its own brand business. After the investment, Legend Capital provided value-added services to the company in various dimensions to support its business at home and abroad, including supply chain resource introduction, business sales channel connection, financial and legal compliance, and talent introduction.

QIN Hua, Chairman and CEO of Gambol Pet, said: “Gambol Pet will take the listing as an opportunity to firmly grasp the strategic window of the rapid development of the pet industry in China. We will adapt to the changes and dynamic trends in pet culture, consumer upgrades, and consumption concepts and continue increasing our products’ market share in domestic and overseas markets. Simultaneously, by continuing to accelerate our global expansion and build our global advantages in technologies, talents, markets, and supply chains, we will keep moving forward and strive to become a highly innovative international enterprise with substantial growth, as well as a leading player in the global pet food industry.”

Raymond CHEN, Co-Chief Investment Officer of Legend Capital, said: “With the continuous improvement of people’s living standards, more and more people are getting emotionally attached to pets. The pet industry in China is in its early stages and enjoys broad prospects for future development. Gambol Pet adheres to continuous innovation and emphasizes proprietary brands. Through independent R&D and product innovation, it has formed its core brand, Myfoodie, which surpassed many imported brands and helped Gambol Pet consolidate its leading position in the pet food industry. Mr. QIN Hua, Chairman of the company, is an outstanding entrepreneur with both local experience and a global vision, and we are proud of the team for achieving this remarkable achievement. Congratulations to Gambol Pet on its successful listing.”

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

The article is distributed by Ever Bloom (HK) Communications Consultants Group Limited on behalf of Legend Capital.

For further information, please contact:
Ms. Orianna Ou / Ms. Arina He
Tel: +852 3468 8171
Email: legendcapital.list@everbloom.com.cn

Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held

On 27 July 2023, on the eve of the highly anticipated Chengdu FISU World University Games, the Minister of Health Indonesia Budi Gunadi Sadikin accompanied Indonesian President Joko Widodo on a visit to China. The Indonesia-China Healthcare and Biotech Investment Forum, co-hosted by the Embassy of the Republic of Indonesia in China and the Indonesian Chamber of Commerce and Industry Bilateral Committee for China (KIKT), and supported by Legend Capital and Indonesia Chamber of Commerce in China (INACHAM), was successfully held at the Shangri-La Hotel in Chengdu. A total of 120 people, including Indonesian government officials, scholars, business people and leading Chinese healthcare companies, attended the event to jointly discuss the direction and opportunities for the development of healthcare and biotech in China and Indonesia.

Frank HONG, Managing Director of Legend Capital

The forum was chaired by Mr. Jafar WANG, Co-Chief Investment Officer of Legend Capital, who mentioned Legend Capital’s latest “Ecosystem plus” strategy in healthcare, and hoped to collaborate with the excellent healthcare enterprises in China and Indonesia to build an open, innovative, and international ecosystem through this forum. Mr. Garibaldi Thohir, Chairman of Indonesia Chamber of Commerce and Industry Bilateral Committee of China (KIKT), Mr. H.E. Djauhari Oratmangun, Indonesian Ambassador to the People’s Republic of China, and Mr. Arsjad Rasjid, Chairman of Indonesia Chamber of Commerce and Industry (KADIN), each delivered opening speeches for the forum. They warmly welcomed Chinese healthcare companies investing and developing in Indonesia, combining innovative technologies, advanced concepts, and China’s experience with Indonesia’s national conditions, to promote the development of Indonesian healthcare and medical services.

The Minister of Health Indonesia, Budi Gunadi Sadikin, delivered a keynote speech on “Healthcare Policy and Planning in Indonesia”. The speech systematically sorted out and discussed the overall health system in Indonesia from various perspectives, such as the current situation of Indonesian healthcare, the number and capabilities of medical personnel, the distribution of medical resources, and the coverage of universal health insurance. He indicated that the Indonesian healthcare system urgently needs to transform and develop, hoping to promote the transformation and upgrading of the healthcare system through the establishment of a nationwide disease prevention and control monitoring network, improving the level of primary healthcare services in Indonesia, training medical professionals and medical staffs, making rational use of funds from all parties, as well as cooperating deeply with Chinese companies through national projects. At last, He warmly welcomed Chinese companies to invest and develop in Indonesia and explore new opportunities and potentials for the development of the healthcare industry in both countries.

Mr. Frank HONG, Managing Director of Legend Capital, then delivered a speech on “Trends in Investment and Industrial Cooperation in Indonesia”, sharing Legend Capital’s investment strategies and choice of approaches in Southeast Asia, especially in Indonesia. He also elaborated on the current situation and upgrade demands of the Indonesian healthcare industry and suggested that excellent Chinese healthcare companies go abroad, increase investment in Indonesia and create more value for the two countries.

Subsequently, under the witness of the Minister of Health Indonesia and relevant government officials, the Ministry of Health Indonesia and Tsinghua University signed a strategic cooperation agreement. At the same time, a signing ceremony was also held between Chinese and Indonesian companies, whereby Chinese companies, including Sansure Biotech, Walvax Biotech, CanSino Bio, BGI, Sinovac Biotech, Zhifei Biological, and Wondfo Biotech, together with Indonesian companies such as UBC Medical, ETANA, Kalbe Farma, BioFarma, and Kimia Farma, reached partnership agreements, jointly supporting the coordinated development of the healthcare fields in China and Indonesia.

Mr. LI Ning, Vice President of BGI Group, gave a speech on “Trends in Life Science Technology”, stating that BGI Group hopes to lead the innovative development of genomics with the integrated development model of “industry, university, and R&D”, promote the transformation of gene technology achievements, and realize the benefits of gene technology to humankind.

During the panel discussion, Mr. Bonanza Perwira, Director of Centre for Global Health and Technology Policy of the Indonesian Ministry of Health, chaired a discussion on the “Prospects for Industrial Cooperation between China and Indonesia”, which the Minister of Health Indonesia Mr. Budi Gunadi Sadikin, Director General of Pharmaceuticals and Medical Devices of the Indonesian Ministry of Health Ms. Lucia Rizka Andalucia, Chairman of Indonesia Chamber of Commerce and Industry Mr. Arsjad Rasjid, Kimia Farma’s President Director Mr. David Utama, and Kalbe Farma’s President Mr. Vidjongtius participated in and responded to questions raised by the audience regarding Indonesian healthcare policies, Indonesian health insurance payment methods, foreign company access and commercialization, and partner selection, and expressed a warm welcome to more open cooperation with Chinese companies.

Subsequently, Mr. QI Fei, Executive Director of Legend Capital, presided over the panel discussion of “Attempts for Chinese Company Collaborating in Indonesia”, which Mr. DAI Lizhong, Chairman and Founder of Sansure Biotech, Mr. WU Xiaobin, President and Chief Operations Officer of BeiGene, Mr. DONG Shaozhong, Vice President of Walvax Biotech, Ms. WANG Jing, Chief Commercial Officer and Executive Director of CanSino Bio, Mr. XIA Jusong, President of International Business at United Imaging Healthcare, and Mr. CHEN Kai, Executive Director of AstraZeneca China participated in and shared and discussed topics such as the trend of China-Indonesia cooperation, development opportunities in Indonesia, practical experience of entering the Indonesian market, and cooperation models between the two countries. It is hoped that Chinese healthcare enterprises can carry out broader and deeper cooperation with more countries to benefit more people around the world.

2023 is the 10th anniversary of the establishment of the China-Indonesia Comprehensive Strategic Partnership and is also a year of opportunities for both countries. With the joint efforts of both sides, it is believed that the collaborative development of China-Indonesia in healthcare fields will undoubtedly contribute to the building of a community with a shared future for human health.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).

One More IPO of Legend Capital: Medical Device Supply Chain Service Provider GKHT Medical Goes Public Successfully

On July 12, Legend Capital‘s portfolio company, GKHT Medical Technology Co., Ltd. (GKHT Medical; Stock Code: 301370.SZ), was successfully listed on the ChiNext Market of the Shenzhen Stock Exchange.

GKHT Medical is a leading comprehensive digital supply chain service provider for medical devices in China. Focusing on the field of medical devices, the company specializes in providing customized supply chain solutions to manufacturing enterprises, distributors/dealers, and medical institutions based on its entire supply chain service-covered platform for every medical device product from original manufacturers to operating rooms.

Starting with high-value medical consumables, GKHT Medical has innovatively created a brand-new business model of the “one-stop distribution platform + hospital-end service platform”, enabling the company to provide the industry with comprehensive digital supply chain services from original manufacturers to operating rooms through intensively integrating key elements such as funds, warehousing, logistics, and circulation process information.

As one of the company’s earliest investors, Legend Capital participated in GKHT Medical’s fundraising rounds in 2016 and 2019 and has kept helping enhance the company’s management and operational capabilities and connect upstream and downstream customer resources since the investments. Over the seven years of investment cooperation, GKHT Medical’s revenue has increased by more than 600%, and it has grown into a tier-one company in the field of high-value consumables for medical devices.

Joe ZHOU, Managing Director of Legend Capital, said: “GKHT Medical has an aspiring and dedicated team whose members have extensive experience in business operations and marketing and jointly drive pragmatic progress through the bonding of each other’s talents. The high-value medical consumables market in China is worth over RMB100 billion, but most supply chain links, such as distribution, are still dominated by traditional agency models. The market is still open to be explored by disruptive innovators, and we believe that GKHT Medical will stand out in the future and continue to support innovation in the field of medical devices.”

“It is believed that the listing will help GKHT Medical to further strengthen its cooperation with upstream and downstream partners, expand the coverage of its direct sales business to more terminal medical institutions, enhance operational funding, and improve its information systems and logistics warehousing system. With improved comprehensive service support capabilities and risk control capabilities, the company is well prepared to meet the changing needs of customers in different markets. At the same time, by deepening the links between the upstream and downstream of the industrial chain and expanding the supply chain business, GKHT Medical is capable of providing customers with digital supply chain services covering high-value consumables, low-value consumables, IVD, and equipment in the medical devices field. The company has established a channel of “manufacturers-GKHT Medical-hospitals” to continuously strengthen its core competitiveness as a comprehensive digital supply chain service provider for medical devices.” Joe Zhou added.

At present, GKHT Medical has provided professional services for more than 100 leading original manufacturers of medical devices and more than 4,000 hospitals worldwide, and it has achieved high-quality and scale development with the capability of delivering to more than 80% of Chinese tertiary hospitals within 2 hours.

Legend Capital has long been paying attention to the investment in the field of medical devices and diagnostics with a focus on three major themes: first, major diseases, especially the unmet clinical needs of chronic diseases; second, the first and uniqueness in technology, which enables a company to become or have the potential to become a leading player in subdivided industries; the third is the “device +” investment opportunities brought by the integration of medical devices and interdisciplinary technologies such as AI, IoT and Big Data. At present, Legend Capital has invested in numerous leading companies in the subdivided industries, including GKHT Medical (301370.SZ), Careray Digital Medical Technology (688607.SH), Axonics (AXNX), New Horizon Health (06606.HK), Wuhan Easy Diagnosis Biomedicine (002932.SZ), Berry Genomics (000710.SZ), Aohua Photoelectricity Endoscope (688212.SH), Chemclin Diagnostics (688468.SH), Bio-heart Biological (02185.HK), STAR Sports Medicine, ET Healthcare, Hailai Xinchuang Medical Technology, and Dearer Medical.

Legend Capital has been actively investing in the healthcare industry since 2007 and has built a distinctive and valuable healthcare ecosystem. The company has created a powerful investment base on the strength of many pillar enterprises it invested in multiple subdivided healthcare industries. In response to changes in the external environment, Legend Capital has proposed a new “healthcare ecosystem +” strategy aiming at the new development pattern of the healthcare industry. By taking capital as the link and focusing on “innovation” and “ecosystems”, Legend Capital intends to build a more extensive ecosystem that connects resources from various sectors, including the industry, academia, and society, to accelerate the transformation of R&D results, promote industrial upgrading, and achieve high-quality development.

About Legend Capital
Founded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.

It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors.

Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.

For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ).